Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib

JAMA Ophthalmology

Volumn 132, Issue 12, 2014, Pages 1421-1425

  Guedj, Mikael ^a   Quéant, Astrid ^a,b   Funck Brentano, Elisa ^c   Kramkimel, Nora ^b,d   Lellouch, Judith ^a,c   Monnet, Dominique ^a,b   Longvert, Christine ^c   Gantzer, Amelie ^c   Brézin, Antoine P ^a,b  

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

^d Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VEMURAFENIB; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; RAF PROTEIN; SULFONAMIDE;

AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CUTANEOUS MELANOMA; DISEASE SEVERITY; EYE INFLAMMATION; FEMALE; HUMAN; INTERMEDIATE UVEITIS; IRIDOCYCLITIS; MACULAR EDEMA; MALE; METASTASIS; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETINA DETACHMENT; RISK ASSESSMENT; SLIT LAMP; UVEITIS; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CASE REPORT; CHEMICALLY INDUCED; MELANOMA; SCLERITIS; SKIN NEOPLASMS; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; PROTEIN KINASE INHIBITORS; RAF KINASES; SCLERITIS; SKIN NEOPLASMS; SULFONAMIDES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; UVEITIS;

EID: 84918520556     PISSN: 21686165     EISSN: 21686173     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2014.3024     Document Type: Article

References (7)

1. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819
2. Chapman PB, Hauschild A,Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-2516
3. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714
4. Korn EL, Liu PY, Lee SJ, et al.Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527-534
5. Arimone Y, Bidault I, Dutertre JP, et al; Cercle de Reflexion sur l'Imputabilite. Update of the French drug reaction assessment method [in French]. Therapie. 2011;66(6):517-525
6. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-1259
7. da Rocha Dias S, Salmonson T, van Zwieten-Boot B, et al. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable ormetastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer. 2013;49(7):1654-1661